Skip to main content
Zhejiang Tianyu Pharmaceutical Co., Ltd. logo

Zhejiang Tianyu Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300702 ISIN · CNE1000034X1 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,272 across all filing types
Latest filing 2026-05-26 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 300702

About Zhejiang Tianyu Pharmaceutical Co., Ltd.

https://www.tianyupharm.com

Zhejiang Tianyu Pharmaceutical Co., Ltd. is a technology-driven enterprise specializing in the research, development, manufacturing, and marketing of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The company focuses primarily on cardiovascular therapeutic areas, maintaining a leading global position in the production of Sartan series products, including Valsartan, Losartan, Irbesartan, and Olmesartan. Beyond hypertension treatments, its portfolio extends to anti-diabetic, anti-thrombotic, and anti-hyperlipidemic agents. Operating with high-standard manufacturing facilities, the company adheres to international quality management systems, holding certifications from major regulatory bodies such as the FDA and EDQM. It serves a global clientele, providing high-quality chemical synthesis and contract development and manufacturing organization (CDMO) services to the pharmaceutical industry.

Recent filings

Filing Released Lang Actions
2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 98% confidence The document is an announcement by Zhejiang Tianyu Pharmaceutical Co., Ltd. regarding the implementation of its 2025 annual equity distribution (dividend) plan, specifying per-share dividend amounts, record and ex-dividend dates, distribution methods, and related tax details. This matches a Notice of Dividend Amount filing.
2026-05-26 Chinese
关于控股股东部分股份补充质押的公告
Director's Dealing Classification · 75% confidence The document is a mandatory disclosure by Zhejiang Tianyu Pharmaceutical Co., Ltd. regarding its largest shareholder (and likely director/executive) Lin Jie supplementally pledging part of her personal shareholding as collateral. It details the number of shares pledged, pledge ratios, pledge start/end dates, and cumulative pledge status. This is not a company financial report, capital raising by the company, or stock buyback/issuance, nor is it a dividend or governance code. Instead, it reports a personal share-related transaction by a major shareholder/executive, which best matches the “Director’s Dealing” category (personal share transactions by insiders).
2026-05-20 Chinese
关于变更部分募集资金用途暨新增募集资金投资项目的公告
Capital/Financing Update Classification · 80% confidence The document is a corporate announcement by Zhejiang Tianyu Pharmaceutical Co. regarding the reallocation of proceeds from a prior private share placement (‘募集资金’) and the introduction of a new fund-investment project. It details the original fundraising amount, actual usage to date, the board and shareholder approval process, and regulatory compliance. This is not a periodic financial report, audit, dividend notice, or management change, but rather a financing update on how previously raised capital will be used. Therefore, it best fits the Capital/Financing Update category (CAP).
2026-05-15 Chinese
关于增加2026年度日常关联交易预计额度的公告
Regulatory Filings Classification · 80% confidence The document is a public announcement by Zhejiang Tianyu Pharmaceutical (300702) detailing the board resolutions and approval to increase the 2026 estimated cap for ordinary related‐party transactions. It contains board minutes, transaction parties, pricing principles, and approvals rather than presenting financial statements or serving as an investor presentation. It is a regulatory compliance disclosure specific to related‐party dealings and falls under “General Regulatory Filings” for miscellaneous corporate announcements. Therefore, it is classified as RNS.
2026-05-15 Chinese
2026年第一次职工代表大会决议公告
Board/Management Information Classification · 85% confidence The document is an official announcement by Zhejiang Tianyu Pharmaceutical Co., Ltd. regarding the election of a new worker representative director to its board at the first workers’ congress of 2026. It describes a change in board composition and the qualifications of the newly elected director. This falls squarely under Board/Management Information, as it announces changes in the company's board of directors.
2026-05-15 Chinese
关于召开2026年第二次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 87% confidence The document is a formal notice announcing and detailing the convening of the 2026 second extraordinary general shareholders’ meeting, including agenda items, voting procedures, proxy authorization form, registration instructions, and attachments for shareholders to submit votes. This clearly constitutes proxy solicitation and information materials for a shareholder meeting, matching the definition of a Proxy Solicitation & Information Statement (PSI).
2026-05-15 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.